Recent Articles

No Outcome, No Income
David B. Nash, MD, MBA
October 2019 Vol 12, No 6 - Editorial
Accountability Is Everything: Outcomes-Based Pharmaceutical Agreements
Javier González, PharmD
October 2019 Vol 12, No 6 - Opinion
Employer-Sponsored Wellness Programs for Hypertension and Dyslipidemia in a 2-Hospital Health System
Anne Misher, PharmD, BCACP, BC-ADM, CDE, Jessica Brown, PharmD, Christina Maguire, PharmD, Alix P. Schnibben, PharmD, BCACP, CTTS
October 2019 Vol 12, No 6 - Clinical, Original Article
Stakeholder Perspective
Benefits of Employer-Sponsored Wellness Programs for Chronic Diseases
by F. Randy Vogenberg, PhD
Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States
Michael C. Runken, PharmD, Joshua M. Noone, PhD, Christopher M. Blanchette, PhD, MBA, Emily Zacherle, MS, Reuben Howden, PhD
October 2019 Vol 12, No 6 - Business, Original Research
Stakeholder Perspective
Shared Decision-Making and Payer Preferences: IVIG or SCIG Route of Administration?
by Gary M. Owens, MD
Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer
Krishna Tangirala, MPH, Sreevalsa Appukkuttan, MPH, MBBS, Stacey Simmons, MD
October 2019 Vol 12, No 6 - Business, Original Research

Most Popular Articles

Value-Based Agreements in Healthcare: Willingness versus Ability
Gary Branning, MBA, Michael Lynch, CPA, MBA, Kathryn Hayes
September 2019 Vol 12, No 5 - Industry Trends
Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus
Pragya Rai, MS, Nilanjana Dwibedi, PhD, Mazhgan Rowneki, MPH, Drew A. Helmer, MD, MS, Usha Sambamoorthi, PhD
September 2019 Vol 12, No 5 - Clinical, Original Research
Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present
Cori Gray, PharmD, Catherine E. Cooke, PharmD, MS (PHSR), BCPS, PAHM, Nicole Brandt, PharmD, MBA, BCPP, BCGP, FASCP
September 2019 Vol 12, No 5 - Regulatory, Review Article

Select Drug Profiles

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations
Loretta Fala
Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura
Loretta Fala

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME